AdaptHealth (NASDAQ:AHCO) Price Target Cut to $14.00 by Analysts at UBS Group

AdaptHealth (NASDAQ:AHCO) had its target price decreased by UBS Group from $15.00 to $14.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s price target indicates a potential upside of 22.59% from the company’s previous close.

A number of other research firms also recently commented on AHCO. Royal Bank Of Canada reiterated an “outperform” rating and issued a $13.00 target price on shares of AdaptHealth in a research report on Wednesday, February 25th. Wall Street Zen downgraded AdaptHealth from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings downgraded AdaptHealth from a “hold (c-)” rating to a “sell (d)” rating in a research report on Wednesday, February 25th. Canaccord Genuity Group set a $16.00 target price on AdaptHealth in a research report on Wednesday. Finally, Truist Financial boosted their target price on AdaptHealth from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

AdaptHealth Price Performance

Shares of AdaptHealth stock traded down $0.33 during trading hours on Wednesday, hitting $11.42. The company’s stock had a trading volume of 2,346,092 shares, compared to its average volume of 1,329,352. The business has a 50 day moving average price of $11.23 and a two-hundred day moving average price of $10.38. AdaptHealth has a 12-month low of $7.95 and a 12-month high of $13.43. The company has a market cap of $1.55 billion, a PE ratio of -20.76, a PEG ratio of 1.50 and a beta of 1.57. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.81 and a current ratio of 1.02.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.13). AdaptHealth had a negative net margin of 2.18% and a positive return on equity of 3.42%. The business had revenue of $819.80 million during the quarter, compared to analysts’ expectations of $796.63 million. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. AdaptHealth’s revenue was up 5.4% on a year-over-year basis. Analysts expect that AdaptHealth will post 0.79 earnings per share for the current fiscal year.

Insider Activity at AdaptHealth

In other news, major shareholder Richard M. Cashin, Jr. bought 447,100 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were bought at an average cost of $9.91 per share, for a total transaction of $4,430,761.00. Following the completion of the transaction, the insider owned 16,312,698 shares of the company’s stock, valued at approximately $161,658,837.18. This represents a 2.82% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders bought 2,494,518 shares of company stock valued at $24,352,291 in the last quarter. 1.55% of the stock is currently owned by insiders.

Institutional Investors Weigh In On AdaptHealth

Large investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. increased its stake in AdaptHealth by 433.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 2,585 shares of the company’s stock worth $26,000 after acquiring an additional 2,100 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in AdaptHealth during the third quarter worth approximately $35,000. PNC Financial Services Group Inc. increased its stake in AdaptHealth by 22.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,003 shares of the company’s stock worth $70,000 after acquiring an additional 1,279 shares during the last quarter. Assetmark Inc. increased its stake in AdaptHealth by 54.8% during the first quarter. Assetmark Inc. now owns 6,952 shares of the company’s stock worth $83,000 after acquiring an additional 2,460 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in AdaptHealth by 318.0% during the second quarter. Tower Research Capital LLC TRC now owns 9,592 shares of the company’s stock worth $90,000 after acquiring an additional 7,297 shares during the last quarter. 82.67% of the stock is owned by institutional investors.

Key Headlines Impacting AdaptHealth

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: Q1 revenue topped expectations — AdaptHealth reported $819.8M in revenue (above consensus ~$796.6M), showing 5.4% YoY growth driven in part by capitated business wins. This revenue beat supports top-line momentum. AdaptHealth (NASDAQ:AHCO) beats Q1 CY2026 sales expectations
• Positive Sentiment: Management is increasing investor engagement — AdaptHealth will present at the Bank of America Global Healthcare Conference and other investor events next week, giving investors more access to management outlook and strategy. AdaptHealth Corp. to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Capitated-contract growth is boosting revenue but the deep-dive piece highlights that margin pressures remain — this is a mixed fundamental read: top-line drivers are intact but cost/coverage mix is a risk to near-term profitability. AHCO Q1 deep dive: Capitated growth boosts revenue, margin pressures persist
• Neutral Sentiment: Company posted updated FY2026 revenue guidance roughly in line with consensus (~$3.5B) but EPS guidance disclosure in the filing was unclear, leaving investors without a clean beat-or-miss on full-year profits. That ambiguity can limit upside until guidance detail is clarified. (Guidance update entry)
• Neutral Sentiment: Full Q1 earnings-call transcript is available for investors who want management commentary on margins, payer mix, and cadence of capitated contracts — useful for due diligence but no new headline. AdaptHealth Corp. (AHCO) Q1 2026 Earnings Call Transcript
• Negative Sentiment: EPS missed expectations — AdaptHealth reported ($0.12) EPS vs. consensus ~$0.01, and commentary confirmed negative net margins and ongoing margin pressure; that miss is the primary driver cited for the stock pullback. Why AdaptHealth (AHCO) shares are sliding today

AdaptHealth Company Profile

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.